ATE272719T1 - Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen - Google Patents

Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Info

Publication number
ATE272719T1
ATE272719T1 AT95904188T AT95904188T ATE272719T1 AT E272719 T1 ATE272719 T1 AT E272719T1 AT 95904188 T AT95904188 T AT 95904188T AT 95904188 T AT95904188 T AT 95904188T AT E272719 T1 ATE272719 T1 AT E272719T1
Authority
AT
Austria
Prior art keywords
ligand
dna
receptor
receptors
drugs
Prior art date
Application number
AT95904188T
Other languages
English (en)
Inventor
Lawrence B Hendry
Original Assignee
Lawrence B Hendry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence B Hendry filed Critical Lawrence B Hendry
Application granted granted Critical
Publication of ATE272719T1 publication Critical patent/ATE272719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Computing Systems (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Library & Information Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95904188T 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen ATE272719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15868993A 1993-11-26 1993-11-26
PCT/US1994/013765 WO1995014791A1 (en) 1993-11-26 1994-11-28 Design of drugs involving receptor-ligand-dna interactions

Publications (1)

Publication Number Publication Date
ATE272719T1 true ATE272719T1 (de) 2004-08-15

Family

ID=22569263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904188T ATE272719T1 (de) 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Country Status (8)

Country Link
US (5) US5705335A (de)
EP (1) EP0740708B1 (de)
JP (1) JPH09505603A (de)
AT (1) ATE272719T1 (de)
AU (1) AU1297995A (de)
CA (1) CA2177388A1 (de)
DE (1) DE69433935D1 (de)
WO (1) WO1995014791A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
JP2000501744A (ja) 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ，インコーポレーテッド モルホゲン類似体およびその製法
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US6460014B1 (en) 1997-09-05 2002-10-01 Accelrys Inc. Modeling interactions with atomic parameters including anisotropic dipole polarizability
DE69834828T2 (de) * 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
AU3901099A (en) * 1998-05-12 1999-11-29 Isis Pharmaceuticals, Inc. Characterization of interactions between molecular interaction sites of rna and ligands therefor
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6542858B1 (en) 1998-09-14 2003-04-01 Lion Bioscience Ag Pharmacokinetic-based drug design tool and method
KR100303263B1 (ko) * 1998-10-13 2001-12-01 조양호 벡터를이용한rna분자이차구조의시각화방법
US6298259B1 (en) 1998-10-16 2001-10-02 Univ Minnesota Combined magnetic resonance imaging and magnetic stereotaxis surgical apparatus and processes
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6343257B1 (en) * 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US20030083483A1 (en) * 1999-05-12 2003-05-01 Ecker David J. Molecular interaction sites of vimentin RNA and methods of modulating the same
US6969763B1 (en) 1999-05-12 2005-11-29 Isis Pharmaceuticals, Inc. Molecular interaction sites of interleukin-2 RNA and methods of modulating the same
WO2001071347A1 (en) * 2000-03-23 2001-09-27 California Institute Of Technology Method and apparatus for predicting ligand binding interactions
US20040038429A1 (en) * 2000-11-14 2004-02-26 Shuichi Hirono Method of searching for novel lead compound
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CA2429895A1 (en) 2000-12-09 2002-06-13 The Regents Of The University Of California X ray crystal structures at 5.5 a resolution of functional complexes of the bacterial ribosome containing transfer rna and model messenger rnas
US20030162219A1 (en) * 2000-12-29 2003-08-28 Sem Daniel S. Methods for predicting functional and structural properties of polypeptides using sequence models
US20030013137A1 (en) * 2001-03-13 2003-01-16 Barak Larry S. Automated methods of detecting receptor activity
US20070021917A1 (en) * 2001-04-27 2007-01-25 Arnaout M A 3-structure of a whole integrin $g(a) v$g(b) extracellular region and uses therefor
AU2002367941A1 (en) * 2001-10-23 2004-02-09 Pharmacogenetics Development Company, Inc. Systems and methods for rapid evaluation and design of molecules for predicted biological activity
US20030162202A1 (en) * 2001-11-09 2003-08-28 Becker Kenneth David Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7590517B2 (en) * 2002-05-28 2009-09-15 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
WO2004035789A1 (en) 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Gene families associated with cancers
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
AU2004209457A1 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP1638581A2 (de) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionische immunomodulatorem zur behandlung von asthma und allergien
US8345988B2 (en) * 2004-06-22 2013-01-01 Sri International Method and apparatus for recognizing 3-D objects
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
KR100954322B1 (ko) 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
US20090092631A1 (en) * 2007-03-26 2009-04-09 Tripep Ab Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
WO2009009493A2 (en) 2007-07-09 2009-01-15 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Aegyptin and uses thereof
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
EP2731617A4 (de) 2011-07-12 2015-07-01 Brigham & Womens Hospital Lipidhaltige psa-zusammensetzungen, verfahren zu ihrer isolierung und verwendungsverfahren dafür
CN102798708A (zh) * 2012-08-23 2012-11-28 中国科学院长春应用化学研究所 一种检测配体与靶标结合特异性的方法及药物筛选方法
US10857177B2 (en) 2015-08-19 2020-12-08 President And Fellows Of Harvard College Lipidated PSA compositions and methods
EP3484441A4 (de) 2016-07-15 2020-03-18 President and Fellows of Harvard College Glycolipidzusammensetzungen und verfahren zur verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461619A (en) * 1981-12-29 1984-07-24 Medical College Of Georgia Research Inst. Method of predicting biological activity of compounds by nucleic acid models
US4705796A (en) * 1986-08-25 1987-11-10 Stereochemical Genetics, Inc. Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5238947A (en) * 1990-04-12 1993-08-24 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity
WO1991016309A1 (en) * 1990-04-12 1991-10-31 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity

Also Published As

Publication number Publication date
AU1297995A (en) 1995-06-13
EP0740708B1 (de) 2004-08-04
JPH09505603A (ja) 1997-06-03
US20020064790A1 (en) 2002-05-30
WO1995014791A1 (en) 1995-06-01
DE69433935D1 (de) 2004-09-09
US5705335A (en) 1998-01-06
EP0740708A4 (de) 1999-12-01
EP0740708A1 (de) 1996-11-06
US6306595B1 (en) 2001-10-23
CA2177388A1 (en) 1995-06-01
US5888738A (en) 1999-03-30
US5888741A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
ATE272719T1 (de) Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen
DeMarzo et al. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.
BG105856A (en) Use of hydroxymatairesinol in cancer prevention
DE69627031D1 (de) Dateiprozessor für die verteilung von multimedia-dateien
DE60041589D1 (de) Reparieren von anwendungen, die inkompatibel zum betriebssystem sind durch bereitstellung von stubs für api's
EP0776331A4 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
EP1517235A3 (de) Rahmenwerk zur Markenbildung
Valentin-Opran et al. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.
IL163125A (en) Two tier paste buffer and display
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
MY118655A (en) Method and apparatus for determining the drive letter assignment of a cd-rom drive during initial system setup of a computer system
WO2004088509A3 (en) Apparatus, system and method of appending a group of files to files on a clipboard of a desktop
WO2002037272A3 (en) Improved frameworks for invoking methods in virtual machines
EP1069050A3 (de) Klammer
Socher et al. Distribution of binding sites for the progesterone receptor within chick oviduct chromatin
von Depka et al. Altered Angiogenic Gene Expression Profiles in Porcine Von Willebrand Disease
Gyug AN EDITION OF LENINGRAD, BAN, F. NO. 200: THE LECTIONARY AND PONTIFICAL OF KOTOR.
Ittel et al. DNA-poly (ADP-ribose) polymerase complex: isolation of the DNA wrapping the enzyme molecule
Braf et al. Faster diagnosis of TTP using new Technoscreen Adamts-13 activity assay
Veselá-Prenosilová Zapiski janycara (Book Review)
Carnathan Progesterone withdrawal during midpregnancy in rats: the effect of treatment and duration of withdrawal.
Thottassery Mirex-induced adaptive liver growth: Studies on glucocorticoid receptors and growth-related genes.
Song Mixing visual and textual programming in a functional language.
Ziedonis et al. Depression in Cocaine Abusing Opioid Addicts Treated with Either Buprenorphine or Methadone
Christensen et al. Increased patient acceptance and adherence using a new fetal movement chart

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties